17/11/2017 - 06:28

PharmAust locks down US patent for cancer drugs

17/11/2017 - 06:28


Upgrade your subscription to use this feature.

ASX-listed biotech PharmAust continues to bolster its IP safeguards around its portfolio of anti-cancer treatments, securing a key patent in the US. The latest patent, which secures PharmAust’s IP in the major North American market, relates to the use of a library of cancer fighting compounds owned by Perth-based PharmAust after being developed by Japanese pharma Nihon Nohyaku.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options